Literature DB >> 16782527

Cystic fibrosis: nutritional consequences and management.

John A Dodge1, Dominique Turck.   

Abstract

Life expectancy for patients with Cystic Fibrosis (CF) has steadily improved during the last three decades, and death in childhood is now uncommon. Nutrition is a critical component of the management of CF, and nutritional status is directly associated with both pulmonary status and survival. Expert dietetic care is necessary, and attention must be given to ensuring an adequate energy intake in the face of demands which may be increased by inadequately controlled malabsorption, chronic broncho-pulmonary colonisation by bacteria and fungi, exacerbations of acute lung infection, impaired lung function, and the need for rehabilitation, repair and growth. Pancreatic enzyme replacement therapy (PERT) is needed by up to 90% of CF patients in Northern Europe, where the 'severe' mutation deltaF508 predominates, but a smaller proportion in Mediterranean countries and elsewhere, because pancreatic insufficiency is one of few features of CF which correlate with genotype. Complications of CF including liver disease and CF-related diabetes pose further challenges. In addition, deficiency of specific nutrients including fat soluble vitamins (particularly A, E and K) essential fatty acids and occasionally minerals occur for a variety of reasons. Osteopenia is common and poorly understood. Liver disease increases the likelihood of vitamin D deficiency. Glucose intolerance and diabetes affect at least 25% of CF adults, and the diabetes differs from both types 1 and 2 diabetes mellitus, but it inversely correlates with prognosis. Management consists of anticipating problems and addressing them vigorously as soon as they appear. Supplements of vitamins are routinely given. Energy supplements can be oral, enteral or, rarely, parenteral. All supplements, including PERT, are adjusted to individual needs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16782527     DOI: 10.1016/j.bpg.2005.11.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Gastroenterol        ISSN: 1521-6918            Impact factor:   3.043


  27 in total

Review 1.  Vitamin K supplementation for cystic fibrosis.

Authors:  Vanitha A Jagannath; Zbys Fedorowicz; Vidhu Thaker; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2015-01-18

Review 2.  Vitamin E supplementation in people with cystic fibrosis.

Authors:  Peter O Okebukola; Sonal Kansra; Joanne Barrett
Journal:  Cochrane Database Syst Rev       Date:  2017-03-06

Review 3.  Gastrointestinal Manifestations of Cystic Fibrosis.

Authors:  Thomas Kelly; James Buxbaum
Journal:  Dig Dis Sci       Date:  2015-02-04       Impact factor: 3.199

4.  Vitamin K supplementation for cystic fibrosis.

Authors:  Vanitha A Jagannath; Vidhu Thaker; Anne B Chang; Amy I Price
Journal:  Cochrane Database Syst Rev       Date:  2020-06-04

Review 5.  Vitamin K supplementation for cystic fibrosis.

Authors:  Vanitha A Jagannath; Vidhu Thaker; Anne B Chang; Amy I Price
Journal:  Cochrane Database Syst Rev       Date:  2017-08-22

6.  Changes in Mineral Micronutrient Status During and After Pulmonary Exacerbation in Adults With Cystic Fibrosis.

Authors:  Moon Jeong Lee; Jessica A Alvarez; Ellen M Smith; David W Killilea; James F Chmiel; Patricia M Joseph; Ruth E Grossmann; Amit Gaggar; Thomas R Ziegler; Vin Tangpricha
Journal:  Nutr Clin Pract       Date:  2015-06-15       Impact factor: 3.080

7.  Vitamin d deficiency in cystic fibrosis.

Authors:  William B Hall; Amy A Sparks; Robert M Aris
Journal:  Int J Endocrinol       Date:  2010-01-28       Impact factor: 3.257

8.  Relationship Between Fat-Soluble Vitamin Supplementation and Blood Concentrations in Adolescent and Adult Patients With Cystic Fibrosis.

Authors:  Oranan Siwamogsatham; Wei Dong; Jose N Binongo; Ritam Chowdhury; Jessica A Alvarez; Shawna J Feinman; Jessica Enders; Vin Tangpricha
Journal:  Nutr Clin Pract       Date:  2014-04-17       Impact factor: 3.080

9.  Characterisation of electrogenic nutrient absorption in the Cftr TgH(neoim)Hgu mouse model.

Authors:  B Tóth; S Leonhard-Marek; H J Hedrich; G Breves
Journal:  J Comp Physiol B       Date:  2008-03-28       Impact factor: 2.200

Review 10.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.